A Systematic Review and Meta-analysis of Gene Therapy with Hematopoietic Stem and Progenitor Cells for Monogenic Disorders

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Mar 15

PMID 35288539

Authors

Francesca Tucci

Stefania Galimberti

Luigi Naldini

Maria Grazia Valsecchi

Alessandro Aiuti

Affiliations

Soon will be listed here.

Abstract

Ex-vivo gene therapy (GT) with hematopoietic stem and progenitor cells (HSPCs) engineered with integrating vectors is a promising treatment for monogenic diseases, but lack of centralized databases is hampering an overall outcomes assessment. Here we aim to provide a comprehensive assessment of the short and long term safety of HSPC-GT from trials using different vector platforms. We review systematically the literature on HSPC-GT to describe survival, genotoxicity and engraftment of gene corrected cells. From 1995 to 2020, 55 trials for 14 diseases met inclusion criteria and 406 patients with primary immunodeficiencies (55.2%), metabolic diseases (17.0%), haemoglobinopathies (24.4%) and bone marrow failures (3.4%) were treated with gammaretroviral vector (γRV) (29.1%), self-inactivating γRV (2.2%) or lentiviral vectors (LV) (68.7%). The pooled overall incidence rate of death is 0.9 per 100 person-years of observation (PYO) (95% CI = 0.37-2.17). There are 21 genotoxic events out of 1504.02 PYO, which occurred in γRV trials (0.99 events per 100 PYO, 95% CI = 0.18-5.43) for primary immunodeficiencies. Pooled rate of engraftment is 86.7% (95% CI = 67.1-95.5%) for γRV and 98.7% (95% CI = 94.5-99.7%) for LV HSPC-GT (p = 0.005). Our analyses show stable reconstitution of haematopoiesis in most recipients with superior engraftment and safer profile in patients receiving LV-transduced HSPCs.

Citing Articles

Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History.

Eapen M, Malec L, Armant M, Johnson B, Shi Q, Xu H N Engl J Med. 2025; 392(4):412-414.

PMID: 39842018 PMC: 11756741. DOI: 10.1056/NEJMc2415164.

Gene Therapy for Inherited Liver Disease: To Add or to Edit.

Chen Y, van Til N, Bosma P Int J Mol Sci. 2024; 25(23).

PMID: 39684224 PMC: 11640881. DOI: 10.3390/ijms252312514.

Haploinsufficiency at the CX3CR1 locus of hematopoietic stem cells favors the appearance of microglia-like cells in the central nervous system of transplant recipients.

Montepeloso A, Mattioli D, Pellin D, Peviani M, Genovese P, Biffi A Nat Commun. 2024; 15(1):10192.

PMID: 39587072 PMC: 11589136. DOI: 10.1038/s41467-024-54515-4.

Long-term lineage commitment in haematopoietic stem cell gene therapy.

Calabria A, Spinozzi G, Cesana D, Buscaroli E, Benedicenti F, Pais G Nature. 2024; 636(8041):162-171.

PMID: 39442556 PMC: 11618100. DOI: 10.1038/s41586-024-08250-x.

Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy.

Duncan C, Bledsoe J, Grzywacz B, Beckman A, Bonner M, Eichler F N Engl J Med. 2024; 391(14):1287-1301.

PMID: 39383458 PMC: 11846662. DOI: 10.1056/NEJMoa2405541.

References

Aldenhoven M, Jones S, Bonney D, Borrill R, Coussons M, Mercer J . Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015; 21(6):1106-9. DOI: 10.1016/j.bbmt.2015.02.011. View

Boucher A, Miller W, Shanley R, Ziegler R, Lund T, Raymond G . Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis. 2015; 10:94. PMC: 4545855. DOI: 10.1186/s13023-015-0313-y. View

Malech H, Maples P, Whiting-Theobald N, Linton G, Sekhsaria S, Vowells S . Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A. 1997; 94(22):12133-8. PMC: 23727. DOI: 10.1073/pnas.94.22.12133. View

Slatter M, Rao K, Hamid I, Nademi Z, Chiesa R, Elfeky R . Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience. Biol Blood Marrow Transplant. 2017; 24(3):529-536. DOI: 10.1016/j.bbmt.2017.11.009. View

Raymond G, Aubourg P, Paker A, Escolar M, Fischer A, Blanche S . Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018; 25(3):538-548. DOI: 10.1016/j.bbmt.2018.09.036. View

Stijnen T, Hamza T, Ozdemir P . Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010; 29(29):3046-67. DOI: 10.1002/sim.4040. View

Labrosse R, Chu J, Armant M, Everett J, Pellin D, Kareddy N . Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. 2023; 142(15):1281-1296. PMC: 10731922. DOI: 10.1182/blood.2022019117. View

de Ravin S, Wu X, Moir S, Anaya-OBrien S, Kwatemaa N, Littel P . Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2016; 8(335):335ra57. PMC: 5557273. DOI: 10.1126/scitranslmed.aad8856. View

Hacein-Bey-Abina S, Garrigue A, Wang G, Soulier J, Lim A, Morillon E . Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118(9):3132-42. PMC: 2496963. DOI: 10.1172/JCI35700. View

10.

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

11.

Hacein-Bey Abina S, Gaspar H, Blondeau J, Caccavelli L, Charrier S, Buckland K . Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA. 2015; 313(15):1550-63. PMC: 4942841. DOI: 10.1001/jama.2015.3253. View

12.

Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12(4):401-9. DOI: 10.1038/nm1393. View

13.

Kang E, Choi U, Theobald N, Linton G, Long Priel D, Kuhns D . Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood. 2009; 115(4):783-91. PMC: 2815517. DOI: 10.1182/blood-2009-05-222760. View

14.

Siler U, Paruzynski A, Holtgreve-Grez H, Kuzmenko E, Koehl U, Renner E . Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing. Curr Gene Ther. 2015; 15(4):416-27. DOI: 10.2174/1566523215666150515145255. View

15.

Ginn S, Curtin J, Kramer B, Smyth C, Wong M, Kakakios A . Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia. Med J Aust. 2005; 182(9):458-63. DOI: 10.5694/j.1326-5377.2005.tb06785.x. View

16.

Kang H, Bartholomae C, Paruzynski A, Arens A, Kim S, Yu S . Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. Mol Ther. 2011; 19(11):2092-101. PMC: 3222528. DOI: 10.1038/mt.2011.166. View

17.

Kohn D, Hershfield M, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska E . T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 1998; 4(7):775-80. PMC: 3777239. DOI: 10.1038/nm0798-775. View

18.

Morris E, Fox T, Chakraverty R, Tendeiro R, Snell K, Rivat C . Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. Blood. 2017; 130(11):1327-1335. PMC: 5813727. DOI: 10.1182/blood-2017-04-777136. View

19.

Ferrua F, Cicalese M, Galimberti S, Giannelli S, Dionisio F, Barzaghi F . Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematol. 2019; 6(5):e239-e253. PMC: 6494976. DOI: 10.1016/S2352-3026(19)30021-3. View

20.

Thompson A, Walters M, Kwiatkowski J, Rasko J, Ribeil J, Hongeng S . Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. N Engl J Med. 2018; 378(16):1479-1493. DOI: 10.1056/NEJMoa1705342. View